In bladder cancer, high EHMT2 expression is associated with poor clinical outcomes, and a novel dual G9a/DNMT inhibitor, CM-272, reportedly induces apoptosis and immunogenic cell death42. Here, DNMT1 is linked to urinary bladder carcinoma.